Please login to the form below

Not currently logged in
Email:
Password:

Celerion appoints chief medical officer

Dr Marc Hoffman brings experience from Patient IP and Theorem Clinical Research

Celerion Dr Marc HoffmanClinical research and pharmacology service provider Celerion has appointed Dr Marc Hoffman as chief medical officer.

Dr Hoffman joins Celerion from Patient Identification Platform, where he also served as chief medical officer, overseeing the firm's platform and programmes.

He brings further experience from Theorem Clinical Research, where he was chief medical officer, senior vice president and general manager.

Previously, Dr Hoffman served as vice president of medical and scientific affairs at Covance and vice president of global medical affairs and product safety at Hospira.

He also brings experience as vice president for global regulatory affairs and medical vigilance for Baxter's operations in Asia and the Americas.

Dr Susan Thornton, president and chief executive officer of Celerion, said: “We are pleased to have Marc join our executive leadership team during this exciting period of growth in our company.

“His depth of experience in managing all aspects of global drug development in multiple therapeutic areas will not only make him a valuable asset for our organization but also for our clients.”

27th February 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics